健脾益肾清化汤联合缬沙坦治疗慢性肾小球肾炎患者的疗效分析(1)
[摘要] 目的 研究健脾益腎清化汤联合缬沙坦治疗慢性肾小球肾炎患者的疗效。 方法 方便选取2016年10月—2018年3月该院接收的慢性肾小球肾炎患者92例，随机数字表法分为对照组(n=46)和研究组(n=46)。对照组采用缬沙坦治疗，研究组于对照组基础上加用健脾益肾清化汤治疗。对比两组治疗效果、治疗前后中医证候积分、生活质量(SF-36评分)、血清黄醇结合蛋白(RBP)、血管内皮生长因子(VEGF)及金属蛋白酶组织抑制剂(TIMP-1)水平。 结果 研究组治疗总有效率[95.65%(44/46)]高于对照组[78.26%(36/46)](χ2=6.133，P=0.013);治疗结束后，研究组血清RBP水平(64.04±7.95)mg/L、VEGF水平(34.18±6.65)ng/L、TIMP-1水平(9.34±1.26)μg/L均低于对照组[(74.16±8.62)mg/L、(40.76±7.38)ng/L、(11.83±1.57)μg/L](t1=5.853，P1=0.000;t2=4.492，P2=0.000;t3=8.389，P3=0.000);研究组中医证候积分(0.76±0.18)分低于对照组(0.94±0.16)分，SF-36评分(78.96±8.07)分高于对照组(72.48±7.52)分(t1=5.069，P1=0.000;t2=3.984，P2=0.000)。 结论 健脾益肾清化汤联合缬沙坦治疗慢性肾小球肾炎患者，能有效减轻患者临床症状，降低血清RBP、VEGF、TIMP-1水平，增强疗效，改善预后效果。
, 百拇医药
[关键词] 慢性肾小球肾炎;健脾益肾清化汤;缬沙坦;RBP;VEGF;TIMP-1;预后效果
[中图分类号] R587.2 [文献标识码] A [文章编号] 1674-0742(2019)06(b)-0190-03
[Abstract] Objective To study the curative effect of Jianpi Yishen Qinghua Decoction combined with valsartan in the treatment of patients with chronic glomerulonephritis. Methods A total of 92 patients with chronic glomerulonephritis were convenient selected and enrolled in our hospital from October 2016 to March 2018. The random number table method was divided into control group (n=46) and study group (n=46). The control group was treated with valsartan， and the study group was treated with Jianpi Yishen Qinghua Decoction on the basis of the control group. Comparison of treatment effects， TCM syndrome scores before and after treatment， quality of life (SF-36 score)， serum flavanol binding protein (RBP)， vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase (TIMP-1) levels. Results The total effective rate of treatment in the study group [95.65% (44/46)] was higher than that in the control group [78.26% (36/46)] (χ2=6.133， P=0.013). After the treatment， the serum RBP level of the study group (64.04±7.95)mg/L，VEGF level(34.18±6.65)ng/L， TIMP-1 level (9.34±1.26)μg/L were lower than the control group[(74.16±8.62) mg/L，(40.76±7.38)ng/L， (11.83±1.57)μg/L] (t1=5.853， P1=0.000; t2=4.492， P2=0.000; t3=8.389， P3=0.000); TCM syndrome score of the study group (0.76±0.18)points was lower than the control group(0.94±0.16)points， and the SF-36 score (78.96±8.07)points was higher than the control group (72.48±7.52)points(t1=5.069， P1=0.000; t2=3.984， P2=0.000). Conclusion Jianpi Yishen Qinghua Decoction combined with valsartan in the treatment of patients with chronic glomerulonephritis can effectively alleviate the clinical symptoms， reduce the levels of serum RBP， VEGF and TIMP-1， enhance the curative effect and improve the prognosis., 百拇医药(薛莉 瞿伟)
, 百拇医药
[关键词] 慢性肾小球肾炎;健脾益肾清化汤;缬沙坦;RBP;VEGF;TIMP-1;预后效果
[中图分类号] R587.2 [文献标识码] A [文章编号] 1674-0742(2019)06(b)-0190-03
[Abstract] Objective To study the curative effect of Jianpi Yishen Qinghua Decoction combined with valsartan in the treatment of patients with chronic glomerulonephritis. Methods A total of 92 patients with chronic glomerulonephritis were convenient selected and enrolled in our hospital from October 2016 to March 2018. The random number table method was divided into control group (n=46) and study group (n=46). The control group was treated with valsartan， and the study group was treated with Jianpi Yishen Qinghua Decoction on the basis of the control group. Comparison of treatment effects， TCM syndrome scores before and after treatment， quality of life (SF-36 score)， serum flavanol binding protein (RBP)， vascular endothelial growth factor (VEGF) and tissue inhibitor of metalloproteinase (TIMP-1) levels. Results The total effective rate of treatment in the study group [95.65% (44/46)] was higher than that in the control group [78.26% (36/46)] (χ2=6.133， P=0.013). After the treatment， the serum RBP level of the study group (64.04±7.95)mg/L，VEGF level(34.18±6.65)ng/L， TIMP-1 level (9.34±1.26)μg/L were lower than the control group[(74.16±8.62) mg/L，(40.76±7.38)ng/L， (11.83±1.57)μg/L] (t1=5.853， P1=0.000; t2=4.492， P2=0.000; t3=8.389， P3=0.000); TCM syndrome score of the study group (0.76±0.18)points was lower than the control group(0.94±0.16)points， and the SF-36 score (78.96±8.07)points was higher than the control group (72.48±7.52)points(t1=5.069， P1=0.000; t2=3.984， P2=0.000). Conclusion Jianpi Yishen Qinghua Decoction combined with valsartan in the treatment of patients with chronic glomerulonephritis can effectively alleviate the clinical symptoms， reduce the levels of serum RBP， VEGF and TIMP-1， enhance the curative effect and improve the prognosis., 百拇医药(薛莉 瞿伟)